Risk Factors for Multidrug Resistance in Nosocomial Bacteremia Caused by Extended-Spectrum β-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae
- 1 October 2012
- journal article
- research article
- Published by SAGE Publications in Microbial Drug Resistance
- Vol. 18 (5) , 518-524
Abstract
Increasing multidrug resistance (MDR) among extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae (ESBL-EK) is of a great concern, because the therapeutic options are severely limited. Thus, we performed a case-control study to evaluate risk factors for MDR among nosocomial bacteremia caused by ESBL-EK. All adult patients with ESBL-EK bacteremia from January 2009 through December 2010 were identified at our institution. MDR was defined as ESBL-EK that demonstrated in vitro resistance to trimethoprim-sulfamethoxazole (TMP-SMX), fluoroquinolone (FQ), and gentamicin. Case patients were those with an MDR ESBL-EK isolate, and control patients were those with a non-MDR ESBL-EK isolate. Among a total of 123 ESBL-EK isolates (74 [60.2%] E. coli and 49 [39.8%] K. pneumoniae ) causing nosocomial bacteremia, 33 (26.8%) cases were due to MDR ESBL-EK. In a univariate analysis, the factors significantly associated with acquisition of MDR ESBL-EK were neutropenia, immunosuppressant use, urinary tract infection, and prior use of antibiotics, especially FQ (all p p =0.036), percutaneous tube insertion (OR=4.04; 95% CI=1.56–10.75; p =0.005), and neutropenia (OR=4.22; 95% CI=1.56–11.45; p =0.005) were independent risk factors for MDR among ESBL-EK bacteremia in hospitalized patients. The CTX-M-15 enzyme was predominant in both the MDR ESBL-EK and non-MDR ESBL-EK groups (55% [11/20] vs. 55.6% [15/27]). Our data suggest that strategies designed to reduce MDR in ESBL-EK bacteremia should focus on limiting the use of FQ and minimizing invasive procedures such as tube insertion.Keywords
This publication has 27 references indexed in Scilit:
- Escherichia coli of human and avian origin: detection of clonal groups associated with fluoroquinolone and multidrug resistance in ItalyJournal of Antimicrobial Chemotherapy, 2012
- Incidence of Fluoroquinolone-Resistant and Extended-Spectrum β-Lactamase-Producing Escherichia coli at a Comprehensive Cancer Center in the United StatesChemotherapy, 2011
- Antibiotic use and the risk of carbapenem-resistant extended-spectrum- -lactamase-producing Klebsiella pneumoniae infection in hospitalized patients: results of a double case-control studyJournal of Antimicrobial Chemotherapy, 2011
- Prevalence and characterization of extended-spectrum β-lactamase– and AmpC β-lactamase–producing Escherichia coli: results of the CANWARD 2007–2009 studyDiagnostic Microbiology and Infectious Disease, 2011
- Perils of quinolone exposure in cancer patientsCancer, 2010
- Clinical Practice Guidelines for the Diagnosis and Management of Intravascular Catheter-Related Infection: 2009 Update by the Infectious Diseases Society of AmericaClinical Infectious Diseases, 2009
- Evidence for Clonal Dissemination of the Serotype K1 Klebsiella pneumoniae Strain Causing Invasive Liver Abscesses in KoreaJournal of Clinical Microbiology, 2008
- Exposure to quinolones is associated with carbapenem resistance among colistin-susceptible Acinetobacter baumannii blood isolatesInternational Journal of Antimicrobial Agents, 2007
- CTX-M and SHV-12 β-lactamases are the most common extended-spectrum enzymes in clinical isolates ofEscherichia coliandKlebsiella pneumoniaecollected from 3 university hospitals within KoreaFEMS Microbiology Letters, 2005
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987